Squarepoint Ops LLC Invests $66,000 in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Squarepoint Ops LLC purchased a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,558 shares of the biotechnology company’s stock, valued at approximately $66,000. Squarepoint Ops LLC owned 0.05% of Enanta Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Stonepine Capital Management LLC bought a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth approximately $1,908,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth approximately $192,000. Millennium Management LLC grew its stake in shares of Enanta Pharmaceuticals by 22.7% in the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company’s stock worth $5,158,000 after acquiring an additional 165,692 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Enanta Pharmaceuticals by 51.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 290,011 shares of the biotechnology company’s stock worth $1,668,000 after acquiring an additional 98,285 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of Enanta Pharmaceuticals by 100.8% in the fourth quarter. BNP Paribas Financial Markets now owns 71,104 shares of the biotechnology company’s stock worth $409,000 after acquiring an additional 35,695 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ENTA has been the topic of a number of research reports. Wall Street Zen raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, JMP Securities raised their price objective on shares of Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Enanta Pharmaceuticals Trading Up 1.1%

Shares of ENTA opened at $7.58 on Wednesday. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $17.24. The company has a market cap of $162.04 million, a P/E ratio of -1.53 and a beta of 0.76. The company’s fifty day simple moving average is $5.62 and its 200-day simple moving average is $6.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The company had revenue of $14.93 million during the quarter, compared to analysts’ expectations of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.